

FDA approves two new medications for diabetes

29 September 2015

Copyright © 2015 [HealthDay](#). All rights reserved.



(HealthDay)—Two new diabetes treatments, Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), have been approved by the U.S. Food and Drug Administration.

Tresiba is a long-acting insulin product, the agency said in a news release. It is injected once daily and helps control [blood glucose levels](#) in patients with both type 1 and type 2 diabetes. The FDA also approved a related treatment, Ryzodeg, which combines Tresiba and another insulin.

The FDA said in its news release Friday that Tresiba's overall efficacy and safety were evaluated in numerous trials involving more than 3,700 patients with type 1 and type 2 diabetes. The results showed that reductions in HbA1c were comparable to other long-acting insulin products, the agency added.

Tresiba and Ryzodeg should not be used by [diabetes patients](#) who have high levels of ketones in their blood, and some common effects include episodes of hypoglycemia, allergic reactions, rash, itching, edema, and weight gain, the agency noted.

Both treatments are made by Novo Nordisk, based in Plainsboro, N.J.

More information: [More Information](#)

APA citation: FDA approves two new medications for diabetes (2015, September 29) retrieved 14 July 2022 from <https://medicalxpress.com/news/2015-09-fda-medications-diabetes.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.